Melanoma Clinical Trials

Showing 341-360 of 705 trials

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

NCT02857270

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Advanced CancerMetastatic MelanomaMetastatic Non-small Cell Lung Cancer+1 more

Eli Lilly and Company210 participantsStarted Sep 2016

Washington D.C., District of Columbia, United States • Sarasota, Florida, United States • Boston, Massachusetts, United States +10 more locations

TERMINATEDPHASE1/PHASE2

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

NCT00945269

RATIONALE: White blood cells that have been treated in a laboratory may be able to kill tumor cells in patients with melanoma. Aldesleukin and denileukin diftitox may stimulate the white blood cells to kill melanoma cells. Giving therapeutic autologous lymphocyte therapy together with aldesleukin and denileukin diftitox may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving therapeutic autologous lymphocytes together with aldesleukin and denileukin diftitox and to see how well it works in treating patients with stage III-IV melanoma

Recurrent MelanomaStage III MelanomaStage IV Melanoma

Fred Hutchinson Cancer Center3 participantsStarted Jul 2009

Seattle, Washington, United States

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Related Searches

Virtual Sun Safe Workplaces Ph I

A Prospective Multicenter Sample Collection Study Using Non-invasive Methods to Investigate Mutation Burden in Non-lesional Facial Skin of Patients With a Hx of Skin Cancer

Engaging Moms on Teen Indoor Tanning Through Social Media

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma Patients

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Study of PI-88 in Patients With Advanced Melanoma

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study

Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer

Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma